CD274 and neoplasm: Administration of anti-PD-L1 antibody enhanced the percentage of CD8+ T cells in the spleen (15.3%) and tumor (28.5%) compared to 5.6% of CD8+ T cells in the spleen and 17.6% of CD8+ T cells in tumor of mice treated with NrIgG (Fig 4A, n = 8).